Acute Myocardial Infarction Market Projected to Reach $6 Billion by 2036
News related to:DelveInsight · 2 min read
New York, USA - September 29, 2026 - The Acute Myocardial Infarction (AMI) market is witnessing a significant transformation, driven by the substantial global disease burden and the development of innovative therapies. According to DelveInsight, the AMI market across the seven major markets (United States, Germany, France, Italy, Spain, the United Kingdom, and Japan) was valued at approximately USD 1.6 billion in 2025 and is projected to reach approximately USD 6.0 billion by 2036, growing at a Compound Annual Growth Rate (CAGR) of approximately 13% during 2026-2036.
The market's growth is fueled by the expanding therapeutic landscape and the increasing focus on secondary prevention strategies. Emerging therapies such as selatogrel, dapagliflozin, FDY-5301, dutogliptin, and zalunfiban are being investigated to address additional treatment gaps. These therapies are expected to play a crucial role in driving the market's growth.
DelveInsight's report highlights that approximately 1.5 million AMI incident cases were estimated across the 7MM in 2025. The United States accounted for the largest share of the AMI market among the 7MM. The report also notes that approximately 950,000 male and 550,000 female AMI incident cases were estimated across the 7MM in 2025. Additionally, the report estimated that 510,000 STEMI and 990,000 NSTEMI cases were recorded in 2025.
The current treatment landscape is centered on rapid reperfusion, antithrombotic therapy, lipid-lowering, and long-term cardiovascular risk reduction. Marketed therapies such as LODOCO (colchicine), TNKase (tenecteplase), and REPATHA (evolocumab) are currently being used. The emerging pipeline includes Selatogrel (ACT-246475) from Idorsia Pharmaceuticals and Viatris, Dutogliptin (REC-01) from Recardio, and FARXIGA/FORXIGA (dapagliflozin) from AstraZeneca. These therapies are being developed to address various aspects of AMI management, including ischemia-reperfusion injury and long-term cardiovascular risk reduction.
The competitive landscape includes established pharmaceutical companies such as AGEPHA Pharma, Genentech, Amgen, Merck, Regeneron and Sanofi, Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, and Arrowhead Pharmaceuticals. These companies are contributing to the development of therapies that target different aspects of AMI management.
Recent developments in the AMI market include the completion of enrollment in the pivotal Phase III Iocyte AMI-3 trial evaluating FDY-5301 for ischemia-reperfusion injury following myocardial infarction by Faraday Pharmaceuticals. Additionally, Idorsia Pharmaceuticals and Viatris entered into a global research and development collaboration, with an upfront payment of USD 350 million for the development and commercialization of selatogrel and cenerimod.
The report also provides an epidemiological assessment of AMI patient burden, evaluating the total AMI incident cases, type-specific cases, gender-specific cases, and the distribution across the 7MM. The analysis indicates a higher incident burden among males, with approximately 950,000 male and 550,000 female AMI incident cases in 2025.
In conclusion, the AMI market is expected to grow significantly, driven by the expansion of the therapeutic landscape and the increasing focus on secondary prevention strategies. The development of emerging therapies and the ongoing research by multiple companies are expected to contribute to the market's growth and improve patient outcomes.